As anti-amyloid approaches continue to yield meager benefits for people with Alzheimer’s disease, therapies targeting neurofibrillary tangles are getting more attention. In the October 1 Nature ...

For decades, scientists have measured how specific regions of the brain shrink with age and disease. Other studies have tracked widening sulci or enlarging ventricles. But is parenchymal shrinkage the ...

This widely used tauopathy model was developed at the University of Pennsylvania School of Medicine by Virginia Lee, John Trojanowski, and colleagues. As first reported in 2007 on a mixed background, ...

SORL1 knockout, knockin, and transgenic mice are now in the Research Models database. The database will be updated as more models become available.

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

The verdict is in—but what now? The Centers for Medicare and Medicaid Services will only cover aducanumab in the context of a clinical trial. Impassioned lobbying on both sides of the issue moved the ...

It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...

For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical practice. Now, they are on the cusp. At this year’s ADPD conference, held ...

Reports of severe gastrointestinal events in some participants led the Food and Drug Administration to put four of six Phase 3 trials of encenicline on hold. FORUM Pharmaceuticals of Waltham, ...

After two years, half of AD patients taking gantenerumab become amyloid-negative. One-third develop ARIA-E, usually without symptoms. Lilly’s N3pG, directed against pyroglutamate Aβ, clears plaques in ...

This letter was prompted by your recent perspective paper and the responses it provoked in an Alzforum discussion. Generally, my comments are offered with the intellectual humility required when ...